{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:59:13Z","timestamp":1788357553845,"version":"build-2803163510"},"reference-count":120,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":4064,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2000,12]]},"abstract":"<jats:p>Synercid (RP 59500), the first injectable streptogramin antibiotic, is composed of two semisynthetic pristinamycin derivatives, quinupristin and dalfopristin. Individually, each component has bacteriostatic activity against staphylococci and streptococci, but together, the agents exhibit synergy, leading to bactericidal activity. The combination drug, however, is bacteriostatic against <jats:italic>Enterococcus faecium<\/jats:italic> and has poor activity against <jats:italic>Enterococcus faecalis<\/jats:italic>. Despite a short half\u2010life, an extended postantibiotic effect allows the agent to be dosed every 8\u201312 hours. Both drugs are largely hepatically metabolized and excreted in bile. Although not metabolized by cytochrome P450 3A4, quinupristin\u2010dalfopristin can inhibit agents that are metabolized through this pathway. Dosage adjustments may be necessary in patients with hepatic dysfunction. Alterations in renal function have minimal effects on the agent's pharmacokinetics. Adverse events include arthralgia, myalgias, and infusion\u2010related pain. Based on available data, quinupristin\u2010dalfopristin appears to have a role in treating severely ill patients with infections due to multiresistant gram\u2010positive pathogens.<\/jats:p>","DOI":"10.1592\/phco.20.19.1469.34858","type":"journal-article","created":{"date-parts":[[2004,6,15]],"date-time":"2004-06-15T15:22:20Z","timestamp":1087312940000},"page":"1469-1485","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Quinupristin\u2010Dalfopristin: An Overview"],"prefix":"10.1002","volume":"20","author":[{"suffix":"Jr.","given":"George","family":"Delgado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda M.","family":"Neuhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Bearden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry H.","family":"Danziger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"Food and Drug Administration.FDA web page. 1999;1999. Available from:http:www.fda.gov."},{"key":"e_1_2_1_3_2","volume-title":"Synercid (quinupristin\/dalfopristin) package insert","author":"Rorer Rh\u00f4ne\u2010Poulenc","year":"1999"},{"key":"e_1_2_1_4_2","volume-title":"Formulary fact book","author":"Rorer Rh\u00f4ne\u2010Poulenc","year":"1999"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/30.suppl_A.9"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.suppl_1.7"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199600511-00006"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/30.suppl_A.95"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(98)00005-X"},{"key":"e_1_2_1_10_2","volume-title":"Synercid (quinupristin\u2010dalfopristin) scientific monograph","author":"Rorer Rh\u00f4ne\u2010Poulenc","year":"1999"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(97)00031-X"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/33.4.849"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.3.553"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/30.suppl_A.53"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/30.suppl_A.25"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/30.suppl_A.45"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/30.suppl_A.15"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/30.suppl_A.29"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/30.suppl_A.39"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.4.854"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(93)90113-L"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/30.suppl_A.59"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/30.suppl_A.83"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.1.238"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(95)00068-L"},{"key":"e_1_2_1_26_2","unstructured":"MahayniR. PerriMB DembryLM ZervosMJComparative in vitro and bactericidal activity of RP 59500 (quinupristin\/dalfopristin) against multi\u2010drug resistantE. faecium. Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy Orlando FL October 47 1994."},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.3.598"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(94)00113-B"},{"key":"e_1_2_1_29_2","unstructured":"CasewellMW Seyed\u2010AkhavaniM. WadeJ.In vitro activity of RP 59500 against vancomycin\u2010resistantEnterococcus faeciumalso resistant to > 512 mg\/L of gentamicin. Presented at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans LA October 1720 1993."},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01709476"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.9.2117"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.suppl_1.67"},{"key":"e_1_2_1_33_2","unstructured":"NeuHC ChinNX WuJF HuangHBEffect of medium upon the MIC values of Synercid (RP 59500) againstHaemophilus influenzae. Presented at the 33rd Interscience Conference of Antimicrobial Agents and Chemotherapy New Orleans LA October 1720 1993."},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.suppl_1.59"},{"key":"e_1_2_1_35_2","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1128\/AAC.42.3.698","article-title":"In vitro activities of quinupristin\u2010dalfopristin and the streptogramin RPR 106972 against Mycoplasma pneumoniae","volume":"42","author":"Izumikawa K.","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_36_2","unstructured":"RenaudinH. BoussensB. BebearC.In vitro activity of RP 59500 againstMycoplasma. Presented at the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago IL September 29October 2 1991."},{"key":"e_1_2_1_37_2","unstructured":"RidgwayGL SalmanH. DencerC. et al.The in vitro activity of Synercid (RP 59500) and RP 106972 againstChlamydiaspp. Mycoplasmaspp. andUreaplasma urealyticum. Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto Ontario Canada September 28October 1 1997."},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01989985"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(96)00129-0"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/30.suppl_A.77"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/32.2.223"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01975171"},{"key":"e_1_2_1_43_2","unstructured":"BaqueroF. BremmelgaardA. MittermayerH. et al.Evaluation of the \u201cin vitro\u201d activity of RP 59500 against anaerobic bacteria: a collaborative European study. Presented at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans LA October 1720 1993."},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.2.213"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/42.6.711"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.4.856"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/30.suppl_A.19"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/30.1.27"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)80002-3"},{"key":"e_1_2_1_50_2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1128\/AAC.43.3.717","article-title":"Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin\u2010sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycinintermediate Staphylococcus aureus by time\u2010kill curve methods","volume":"43","author":"Hershberger E.","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_51_2","unstructured":"VouillamozJ. EntenzaJM GiddeyM. GlauserMP MoreillonP.In vitro activity of Synercid (quinupristin\/dalfopristin) (SYN) combined with other classes of antibiotics against vancomycin\u2010susceptible (VS)E. faecalisand vancomycin\u2010susceptible or \u2010resistant (VR)E. faecium(VSEF and VREF). Presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans LA September 1518 1996."},{"key":"e_1_2_1_52_2","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1128\/AAC.42.10.2710","article-title":"Treatment of vancomycin\u2010resistant Enterococcus faecium with RP 59500 (quinupristin\u2010dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations","volume":"42","author":"Aeschlimann J.R.","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(97)81811-1"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1086\/517755"},{"key":"e_1_2_1_55_2","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1128\/AAC.43.11.2776","article-title":"Synergy testing of vancomycin\u2010resistant Enterococcus faecium against quinupristin\u2010dalfopristin in combination with other antimicrobial agents","volume":"43","author":"Matsumura SO","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.suppl_1.63"},{"key":"e_1_2_1_57_2","unstructured":"VouillamozJ. EntenzaJM BarryA. FegerC. GlauserMP MoreillonP.In vitro bactericidal antagonism of Synercid (SYN) and beta\u2010lactam against methicillin\u2010resistantStaphylococcus aureus(MRSA) does not predict treatment failure in experimental endocarditis (EE). Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco CA September 2629 1999."},{"key":"e_1_2_1_58_2","unstructured":"VouillamozJ. EntenzaJM GiddeyM. GlauserMP MoreillonP.Synercid (SYN) alone or combined with cefepime (FEP) in the treatment (Rx) of experimental endocarditis (EE) due to methicillin\u2010resistantStaphylococcus aureus(MRSA) resistant to macrolide\u2010lincosamide\u2010streptogramin B (MLSB\u2010R). Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego CA September 2427 1998."},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/41.3.349"},{"key":"e_1_2_1_60_2","unstructured":"VouillamozJ. EntenzaJM GiddeyM. GlauserMP MoreillonP.In vitro efficacy of Synercid (quinupristin\/dalfopristin) (SYN) combined with other classes of antibiotics against methicillin\u2010susceptible and \u2010resistantStaphylococcus aureus(MSSA and MRSA). Presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans LA September 1518 1996."},{"key":"e_1_2_1_61_2","unstructured":"ZarroukV. BozdoganB. LeclercqR. GarryL. CarbonC. FantinB.Quinupristin\u2010dalfopristin (Q\u2010D) alone or in combination with rifampin (Rif) in vitro and in experimental endocarditis caused byStaphylococcus aureusharboring different phenotypes of resistance to quinupristin or dalfopristin. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco CA September 2629 1999."},{"key":"e_1_2_1_62_2","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1128\/AAC.43.8.2097","article-title":"Plasmid\u2010mediated coresistance to streptogramins and vancomycin in Enterococcus faecium HM1032 [letter]","volume":"43","author":"Bozdogan B.","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01961676"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/30.suppl_A.101"},{"key":"e_1_2_1_65_2","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1128\/AAC.42.11.3028","article-title":"Postantibiotic effect and postantibiotic sub\u2010MIC effect of quinupristin\u2010dalfopristin against gram\u2010positive and \u2010negative organisms","volume":"42","author":"Pankuch GA","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_66_2","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1128\/AAC.42.9.2188","article-title":"Pharmacodynamic analysis of the activity of quinupristin\u2010dalfopristin against vancomycin\u2010resistant Enterococcus faecium with differing MBCs via time\u2010kill\u2010curve and postantibiotic effect methods","volume":"42","author":"Aeschlimann J.R.","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_67_2","unstructured":"CraigW. EbertS.Pharmacodynamic activities of RP 59500 in an animal infection model. Presented at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans LA October 1720 1993."},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.5.1062"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.7.1273"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.7.1267"},{"key":"e_1_2_1_71_2","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1128\/AAC.41.5.931","article-title":"Influence of inducible cross\u2010resistance to macrolides, lincosamides, and streptogramin B\u2010type antibiotics in Enterococcus faecium on activity of quinupristin\u2010dalfopristin in vitro and in rabbits with experimental endocarditis","volume":"41","author":"Fantin B.","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.1.19"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.11.2523"},{"key":"e_1_2_1_74_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.suppl_1.129"},{"key":"e_1_2_1_75_2","unstructured":"GaillardC. VanCantfortJ. MontayG. et al.Disposition of the radiolabelled streptogramin RP 59500 in healthy male volunteers. Presented at the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy Anaheim CA October 1114 1992."},{"key":"e_1_2_1_76_2","unstructured":"MontayG. LeLibouxA. EtienneS. PanisR.RP 59500 pharmacokinetics after single dose administration in healthy volunteers. Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy Orlando FL October 47 1994."},{"key":"e_1_2_1_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(20)30278-6"},{"key":"e_1_2_1_78_2","unstructured":"ChevalierP. ReyJ. Rouzier\u2010PanisR. HardingN. MontayG.Multiple\u2010dose pharmacokinetics and safety of quinupristin\/dalfopristin (Q\/D RP 59500 Synercid) in healthy volunteers. Presented at the 20th International Congress of Chemotherapy Sydney Australia June 29July 3 1997."},{"key":"e_1_2_1_79_2","unstructured":"ChevalierP. ReyJ. BoucherE. et al.Open comparative study of the pharmacokinetics and safety of a single dose of quinupristin\/dalfopristin (Q\/D RP 59500 Synercid) in subjects with hepatic cirrhosis and healthy volunteers. Presented at the 20th International Congress of Chemotherapy Sydney Australia June 29July 3 1997."},{"key":"e_1_2_1_80_2","unstructured":"LefebvreP. ReyJ. MorganrothJ. GearyW. MontayG.Open comparative study of the safety of a single dose of quinupristin\/dalfopristin (Q\/D RP 59500 Synercid) in obese and in non\u2010obese male subjects. Presented at the 20th International Congress of Chemotherapy Sydney Australia June 29July 3 1997."},{"key":"e_1_2_1_81_2","unstructured":"ChevalierP. ReyJ. FrankH. et al.Open comparative study of the pharmacokinetics and safety of a single dose of quinupristin\/dalfopristin (Q\/D RP 59500 Synercid) in patients with severe chronic renal failure and in healthy volunteers. Presented at the 20th International Congress of Chemotherapy Sydney Australia June 29July 3 1997."},{"key":"e_1_2_1_82_2","unstructured":"LefebvreP. GearyB. ReyJ. MorganrothJ. MontayG.Open comparative study of the pharmacokinetic and safety of a single dose of quinupristin\/dalfopristin (Q\/D RP 59500 Synercid) in healthy male and female volunteers. Presented at the 20th International Congress of Chemotherapy Sydney Australia June 29July 3 1997."},{"key":"e_1_2_1_83_2","unstructured":"LefebvreP. ReyJ. HardingN. PanisR. MontayG.Open comparative study of the pharmacokinetic and safety of a single dose of quinupristin\/dalfopristin (Q\/D RP 59500 Synercid) in healthy elderly volunteers and healthy young volunteers. Presented at the 20th International Congress of Chemotherapy Sydney Australia June 29July 3 1997."},{"key":"e_1_2_1_84_2","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_2_1_85_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.2.400"},{"key":"e_1_2_1_86_2","doi-asserted-by":"publisher","DOI":"10.1097\/00024382-199607000-00007"},{"key":"e_1_2_1_87_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.7.3713"},{"key":"e_1_2_1_88_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/30.suppl_A.107"},{"key":"e_1_2_1_89_2","unstructured":"BallowCH GearyWJ TurnakMR HuangY. ReyJV HyattJMUptake of quinupristin\/dalfopristin (Q\/D) into polymorphonuclear leukocytes (PMNs) in normal volunteers. Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego CA September 2427 1998."},{"key":"e_1_2_1_90_2","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1128\/AAC.40.4.886","article-title":"Intracellular activities of RP 59500 (quinupristin\u2010dalfopristin) and sparfloxacin against Enterococcus faecium","volume":"40","author":"Herrera\u2010Insua I.","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_91_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.3.277"},{"key":"e_1_2_1_92_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02276064"},{"key":"e_1_2_1_93_2","unstructured":"BergeronMG TrottierS. LepageMC et al.A phase I open\u2010label single\u2010dose study of blood and blister fluid pharmacokinetics of quinupristin\/dalfopristin (Q\/D RP 59500 Synercid). Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto Ontario Canada September 28October 1 1997."},{"key":"e_1_2_1_94_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.1.87"},{"key":"e_1_2_1_95_2","unstructured":"GareyKW TesoroE. MuggiaV. et al.Cerebrospinal fluid concentrations of quinupristin\/dalfopristin. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto Ontario Canada September 1720 2000."},{"key":"e_1_2_1_96_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.2.263"},{"key":"e_1_2_1_97_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.2.251"},{"key":"e_1_2_1_98_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.suppl_1.145"},{"key":"e_1_2_1_99_2","unstructured":"TalbotG. BarriereS. CerwinkaS. et al.Efficacy of quinupristin\/dalfopristin (Synercid RP 59500) in the treatment of patients with positive blood cultures in global phase III studies [abstr]. Presented at the 20th International Congress of Chemotherapy Sydney Australia June 29July 3 1997."},{"key":"e_1_2_1_100_2","doi-asserted-by":"publisher","DOI":"10.1007\/s100960050258"},{"key":"e_1_2_1_101_2","first-page":"169","article-title":"Quinupristin\/dalfopristin (Synercid) therapy of methicillin\u2010resistant Staphylococcus aureus infections [abstr]","volume":"44","author":"Srinath L.","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"e_1_2_1_102_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.3.9904115"},{"key":"e_1_2_1_103_2","unstructured":"BaughmanR.Randomized double blind comparative multicenter study of quinupristin\/dalfopristin (Q\/D RP 59500 Synercid) versus combination of ceftriaxone and erythromycin in the treatment of acute community\u2010acquired bacterial pneumonia (CAP) [abstr]. Presented at the 20th International Congress of Chemotherapy Sydney Australia June 29July 3 1997."},{"key":"e_1_2_1_104_2","doi-asserted-by":"publisher","DOI":"10.1086\/516895"},{"key":"e_1_2_1_105_2","doi-asserted-by":"publisher","DOI":"10.1086\/598358"},{"key":"e_1_2_1_106_2","doi-asserted-by":"publisher","DOI":"10.7547\/87507315-87-9-434"},{"key":"e_1_2_1_107_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1996.00440210097010"},{"key":"e_1_2_1_108_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.1996.2.407"},{"key":"e_1_2_1_109_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199652030-00006"},{"key":"e_1_2_1_110_2","unstructured":"BompartF. DorrMB BekeleT. et al.Overview of the safety and tolerability of quinupristin\/dalfopristin (Synercid) in the global development program. Presented at the 4th International Conference on the Macrolides Azalides Streptogramins and Ketolides Barcelona Spain January 2123 1998."},{"key":"e_1_2_1_111_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.suppl_1.37"},{"key":"e_1_2_1_112_2","unstructured":"TalbotGH ZhuGRCharacteristics of arthralgias\/myalgias associated with quinupristin\/dalfopristin (Q\/D Synercid). Presented at the 36th annual meeting of the Infectious Diseases Society of America Denver Co. November 1215 1998."},{"key":"e_1_2_1_113_2","unstructured":"BallowCH ChevalierPJ GearyWJ ReyJV MontayG. SanderinkG.Cytochrome P\u2010450 3A4 (CYP3A4) inhibition by quinupristin\/dalfopristin (Q\/D): interaction with nifedipine (N) in normal volunteers. Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego CA September 2427 1998."},{"key":"e_1_2_1_114_2","volume-title":"Effect of quinupristin\/dalfopristin on FK\u2010506 (tacrolimus) blood levels in liver transplanted recipients Presented at the 4th International Conference on the Macrolides, Azalides","author":"Linden PK","year":"1998"},{"key":"e_1_2_1_115_2","unstructured":"BallowC. ChevalierP. ForrestA. GearyB. MontayG. ReyJ.Randomized crossover phase I study of the interaction between quinupristin\/dalfopristin (Q\/D RP 59500 Synercid) at steady state and cyclosporine in healthy volunteers. Presented at the 20th Interscience Congress of Chemotherapy Sydney Australia June 29July 3 1997."},{"key":"e_1_2_1_116_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809703100509"},{"key":"e_1_2_1_117_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)00109-6"},{"key":"e_1_2_1_118_2","volume-title":"Red book 2000. Drug topics","year":"2000"},{"key":"e_1_2_1_119_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.7.1838-1841.2000"},{"key":"e_1_2_1_120_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.1062-1066.2000"},{"key":"e_1_2_1_121_2","volume-title":"Zyvox (linezolid) package insert","author":"Pharmacia & Upjohn.","year":"2000"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.20.19.1469.34858","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.20.19.1469.34858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:53:41Z","timestamp":1761047621000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.20.19.1469.34858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,12]]},"references-count":120,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2000,12]]}},"alternative-id":["10.1592\/phco.20.19.1469.34858"],"URL":"https:\/\/doi.org\/10.1592\/phco.20.19.1469.34858","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,12]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}